Drug response prediction in high-risk multiple myeloma

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• High-risk myeloma patients often have poor prognoses despite standard treatments.
• Gene expression profiling (GEP) offers insights into individual tumor biology.
• Personalized medicine aims to tailor treatments based on patient-specific molecular data.

Purpose of the Study:

• To develop and validate a Drug Response Prediction (DRP) score using GEP data.
• To assess the DRP score's ability to predict treatment response in high-risk myeloma.
• To identify specific drugs for which predicted sensitivity correlates with improved patient outcomes.

Main Methods:

• Utilized GEP data from high-risk myeloma patients in Total Therapy 2 and 3A trials.
• Developed a DRP score to predict drug response based on GEP signatures.
• Analyzed the correlation between DRP-predicted drug sensitivity and progression-free survival (PFS).

Main Results:

• The DRP score stratified patients, identifying a subset with over 10 years PFS.
• Predicted sensitivity to melphalan was associated with prolonged PFS (HR=2.4, P=0.014).
• Predicted sensitivity to bortezomib showed a significant association with prolonged PFS (HR=5.7, P=0.027) and better treatment response (P=0.022).

Conclusions:

• The DRP score can identify high-risk myeloma patients likely to benefit from specific therapies.
• This GEP-based approach facilitates personalized medicine in myeloma treatment.
• The DRP score may help avoid ineffective treatments and reduce patient toxicity.